{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:44:36Z","timestamp":1793324676103,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute myeloid leukemia (AML) is a rapidly progressing and often fatal hematopoietic malignancy. Venetoclax (VEN), a recent FDA-approved BCL-2 selective inhibitor, has high initial response rates in elderly AML patients, but the majority of patients eventually acquire resistance. Multiple studies have demonstrated that the female sex is associated with better outcomes in patients with AML, which are predominantly attributed to estrogen signaling. As a novel membrane estrogen receptor, G protein-coupled estrogen receptor (GPER)-mediated-rapid estrogen effects have attracted considerable attention. However, whether targeting GPER enhances the antileukemic activity of VEN is unknown. In this study, we first demonstrated that GPER expression was dramatically reduced in AML cells owing to promoter hypermethylation. Furthermore, pharmacological activation of GPER by G-1 combined with VEN resulted in synergistic antileukemic activity in vitro and in vivo. Mechanistically, G-1\/VEN combination synergistically triggered concurrent mitochondria-related apoptosis and gasdermin E (GSDME)-dependent pyroptosis by activating p38-MAPK\/myeloid cell leukemia 1 (MCL-1) axis. Importantly, leukemic pyroptosis heightened CD8+ T cell immune function by releasing interleukin (IL)-1\u03b2\/18 into the tumor microenvironment. Our study corroborates that GPER activation shows a synergistic antileukemic effect with VEN, making it a promising therapeutic regimen for AML.<\/jats:p>","DOI":"10.1038\/s41419-022-05357-9","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T05:02:23Z","timestamp":1667192543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia"],"prefix":"10.1038","volume":"13","author":[{"given":"Jun","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zesong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1097-6034","authenticated-orcid":false,"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"5357_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453\u201374.","journal-title":"Blood."},{"key":"5357_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett A, Wetzler M, L\u00f6wenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487\u201394.","journal-title":"J Clin Oncol"},{"key":"5357_CR3","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026.","journal-title":"BMJ."},{"key":"5357_CR4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s41375-018-0068-2","volume":"32","author":"AK Eisfeld","year":"2018","unstructured":"Eisfeld AK, Kohlschmidt J, Mr\u00f3zek K, Blachly JS, Walker CJ, Nicolet D, et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018;32:1338\u201348.","journal-title":"Leukemia."},{"key":"5357_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood."},{"key":"5357_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"5357_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10:506\u201325.","journal-title":"Cancer Discov"},{"key":"5357_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13:72.","journal-title":"J Hematol Oncol"},{"key":"5357_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/bjh.17523","volume":"194","author":"PH Wiernik","year":"2021","unstructured":"Wiernik PH, Sun Z, Cripe LD, Rowe JM, Fernandez HF, Luger SM, et al. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. Br J Haematol. 2021;194:309\u201318.","journal-title":"Br J Haematol"},{"key":"5357_CR10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.tem.2020.06.001","volume":"31","author":"JP Teoh","year":"2020","unstructured":"Teoh JP, Li X, Simoncini T, Zhu D, Fu X. Estrogen-mediated gaseous signaling molecules in cardiovascular disease. Trends Endocrinol Metab. 2020;31:773\u201384.","journal-title":"Trends Endocrinol Metab"},{"key":"5357_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-physiol-030212-183708","volume":"75","author":"J Liang","year":"2013","unstructured":"Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol. 2013;75:225\u201340.","journal-title":"Annu Rev Physiol"},{"key":"5357_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/0008-5472.CAN-19-0209","volume":"79","author":"RD Roberts","year":"2019","unstructured":"Roberts RD. Is estrogen the answer for osteosarcoma? Cancer Res. 2019;79:1034\u201335.","journal-title":"Cancer Res"},{"key":"5357_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nrd3551","volume":"10","author":"S Nilsson","year":"2011","unstructured":"Nilsson S, Koehler KF, Gustafsson J\u00c5. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov. 2011;10:778\u201392.","journal-title":"Nat Rev Drug Discov"},{"key":"5357_CR14","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1158\/0008-5472.CAN-06-1681","volume":"67","author":"S Agrawal","year":"2007","unstructured":"Agrawal S, Unterberg M, Koschmieder S, zur Stadt U, Brunnberg U, Verbeek W, et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 2007;67:1370\u20137.","journal-title":"Cancer Res"},{"key":"5357_CR15","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/cancers12040907","volume":"12","author":"A Roma","year":"2020","unstructured":"Roma A, Spagnuolo PA. Estrogen receptors alpha and beta in acute myeloid leukemia. Cancers. 2020;12:907.","journal-title":"Cancers"},{"key":"5357_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.stem.2014.11.002","volume":"15","author":"A S\u00e1nchez-Aguilera","year":"2014","unstructured":"S\u00e1nchez-Aguilera A, Arranz L, Mart\u00edn-P\u00e9rez D, Garc\u00eda-Garc\u00eda A, Stavropoulou V, Kubovcakova L, et al. Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell. 2014;15:791\u2013804.","journal-title":"Cell Stem Cell"},{"key":"5357_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3892\/ijo.2016.3348","volume":"48","author":"K Adachi","year":"2016","unstructured":"Adachi K, Honma Y, Miyake T, Kawakami K, Takahashi T, Suzumiya J. Tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of all-trans retinoic acid in acute promyelocytic leukemia cells. Int J Oncol. 2016;48:1095\u2013102.","journal-title":"Int J Oncol"},{"key":"5357_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1124\/pr.114.009712","volume":"67","author":"ER Prossnitz","year":"2015","unstructured":"Prossnitz ER, Arterburn JB. International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharm Rev. 2015;67:505\u201340.","journal-title":"Pharm Rev"},{"key":"5357_CR19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nrendo.2011.122","volume":"7","author":"ER Prossnitz","year":"2011","unstructured":"Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 2011;7:715\u201326.","journal-title":"Nat Rev Endocrinol"},{"key":"5357_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-pharmtox-010716-104651","volume":"57","author":"RD Feldman","year":"2017","unstructured":"Feldman RD, Limbird LE. GPER (GPR30): a nongenomic receptor (GPCR) for steroid hormones with implications for cardiovascular disease and cancer. Annu Rev Pharm Toxicol. 2017;57:567\u201384.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"5357_CR21","doi-asserted-by":"publisher","first-page":"638171","DOI":"10.3389\/fonc.2021.638171","volume":"11","author":"YA Qiu","year":"2021","unstructured":"Qiu YA, Xiong J, Fu Q, Dong Y, Liu M, Peng M, et al. GPER-induced ERK signaling decreases cell viability of hepatocellular carcinoma. Front Oncol. 2021;11:638171.","journal-title":"Front Oncol"},{"key":"5357_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0654-3","volume":"16","author":"Q Liu","year":"2017","unstructured":"Liu Q, Chen Z, Jiang G, Zhou Y, Yang X, Huang H, et al. Epigenetic down regulation of G protein-coupled estrogen receptor (GPER) functions as a tumor suppressor in colorectal cancer. Mol Cancer. 2017;16:87.","journal-title":"Mol Cancer"},{"key":"5357_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jcmgh.2020.04.016","volume":"10","author":"CA Natale","year":"2020","unstructured":"Natale CA, Li J, Pitarresi JR, Norgard RJ, Dentchev T, Capell BC, et al. Pharmacologic activation of the G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma. Cell Mol Gastroenterol Hepatol. 2020;10:868\u201380.e1.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"5357_CR24","doi-asserted-by":"publisher","first-page":"668617","DOI":"10.3389\/fonc.2021.668617","volume":"11","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu T, Yang F, Han J, Zuo B, Huang L, et al. G protein-coupled estrogen receptor agonist G-1 inhibits mantle cell lymphoma growth in preclinical models. Front Oncol. 2021;11:668617.","journal-title":"Front Oncol"},{"key":"5357_CR25","doi-asserted-by":"publisher","first-page":"e31770","DOI":"10.7554\/eLife.31770","volume":"7","author":"CA Natale","year":"2018","unstructured":"Natale CA, Li J, Zhang J, Dahal A, Dentchev T, Stanger BZ, et al. Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. Elife. 2018;7:e31770.","journal-title":"Elife."},{"key":"5357_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"key":"5357_CR27","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood.2020010167","volume":"137","author":"R Thijssen","year":"2021","unstructured":"Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, et al. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021;137:2721\u201335.","journal-title":"Blood."},{"key":"5357_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2019Alessandro A, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9:910\u201325.","journal-title":"Cancer Discov"},{"key":"5357_CR29","doi-asserted-by":"publisher","first-page":"R568","DOI":"10.1016\/j.cub.2016.02.019","volume":"26","author":"L Vande Walle","year":"2016","unstructured":"Vande Walle L, Lamkanfi M. Pyroptosis. Curr Biol. 2016;26:R568\u201372.","journal-title":"Curr Biol"},{"key":"5357_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5357_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41422-022-00653-7","volume":"32","author":"D Tang","year":"2022","unstructured":"Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32:417\u20138.","journal-title":"Cell Res"},{"key":"5357_CR32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.apsb.2020.06.015","volume":"10","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhang P, An L, Sun N, Peng L, Tang W, et al. Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis. Acta Pharm Sin B. 2020;10:1397\u2013413.","journal-title":"Acta Pharm Sin B."},{"key":"5357_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","volume":"42","author":"J Shi","year":"2017","unstructured":"Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem Sci. 2017;42:245\u201354.","journal-title":"Trends Biochem Sci"},{"key":"5357_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660\u20135.","journal-title":"Nature."},{"key":"5357_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547:99\u2013103.","journal-title":"Nature."},{"key":"5357_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579:415\u201320.","journal-title":"Nature."},{"key":"5357_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41392-020-00274-9","volume":"5","author":"Z Peng","year":"2020","unstructured":"Peng Z, Wang P, Song W, Yao Q, Li Y, Liu L, et al. GSDME enhances cisplatin sensitivity to regress non-small cell lung carcinoma by mediating pyroptosis to trigger antitumor immunocyte infiltration. Signal Transduct Target Ther. 2020;5:159.","journal-title":"Signal Transduct Target Ther"},{"key":"5357_CR38","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130:1552\u201364.","journal-title":"J Clin Invest"},{"key":"5357_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14128","volume":"8","author":"C Rogers","year":"2017","unstructured":"Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic\/pyroptotic cell death. Nat Commun. 2017;8:14128.","journal-title":"Nat Commun"},{"key":"5357_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.398","volume":"5","author":"W Wei","year":"2014","unstructured":"Wei W, Chen ZJ, Zhang KS, Yang XL, Wu YM, Chen XH, et al. The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. Cell Death Dis. 2014;5:e1428.","journal-title":"Cell Death Dis"},{"key":"5357_CR41","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1158\/1078-0432.CCR-18-1478","volume":"24","author":"H Lu","year":"2018","unstructured":"Lu H, Zhang S, Wu J, Chen M, Cai MC, Fu Y, et al. Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death. Clin Cancer Res. 2018;24:6066\u201377.","journal-title":"Clin Cancer Res"},{"key":"5357_CR42","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/hep.30666","volume":"70","author":"C Hage","year":"2019","unstructured":"Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, P\u00f6schinger T, et al. Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma. Hepatology. 2019;70:1280\u201397.","journal-title":"Hepatology."},{"key":"5357_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7:51.","journal-title":"Signal Transduct Target Ther"},{"key":"5357_CR44","first-page":"1262","volume":"106","author":"X Li","year":"2021","unstructured":"Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, et al. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2021;106:1262\u201377.","journal-title":"Haematologica."},{"key":"5357_CR45","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41422-018-0090-y","volume":"28","author":"B Zhou","year":"2018","unstructured":"Zhou B, Zhang JY, Liu XS, Chen HZ, Ai YL, Cheng K, et al. Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis. Cell Res. 2018;28:1171\u201385.","journal-title":"Cell Res"},{"key":"5357_CR46","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"5357_CR47","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-17-0292","volume":"16","author":"SG Rota","year":"2017","unstructured":"Rota SG, Roma A, Dude I, Ma C, Stevens R, MacEachern J, et al. Estrogen receptor \u03b2 is a novel target in acute myeloid leukemia. Mol Cancer Ther. 2017;16:2618\u201326.","journal-title":"Mol Cancer Ther"},{"key":"5357_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03804-7","volume":"12","author":"K Long","year":"2021","unstructured":"Long K, Gu L, Li L, Zhang Z, Li E, Zhang Y, et al. Small-molecule inhibition of APE1 induces apoptosis, pyroptosis, and necroptosis in non-small cell lung cancer. Cell Death Dis. 2021;12:503.","journal-title":"Cell Death Dis"},{"key":"5357_CR49","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"X Niu","year":"2016","unstructured":"Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res. 2016;22:4440\u201351.","journal-title":"Clin Cancer Res"},{"key":"5357_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41392-020-0112-3","volume":"5","author":"DA Luedtke","year":"2020","unstructured":"Luedtke DA, Su Y, Ma J, Li X, Buck SA, Edwards H, et al. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduct Target Ther. 2020;5:17.","journal-title":"Signal Transduct Target Ther"},{"key":"5357_CR51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2020.08.018","volume":"492","author":"W Yang","year":"2020","unstructured":"Yang W, Liu S, Li Y, Wang Y, Deng Y, Sun W, et al. Pyridoxine induces monocyte-macrophages death as specific treatment of acute myeloid leukemia. Cancer Lett. 2020;492:96\u2013105.","journal-title":"Cancer Lett"},{"key":"5357_CR52","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41591-018-0082-y","volume":"24","author":"DC Johnson","year":"2018","unstructured":"Johnson DC, Taabazuing CY, Okondo MC, Chui AJ, Rao SD, Brown FC, et al. DPP8\/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med. 2018;24:1151\u20136.","journal-title":"Nat Med"},{"key":"5357_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.492","volume":"11","author":"T Du","year":"2021","unstructured":"Du T, Gao J, Li P, Wang Y, Qi Q, Liu X, et al. Pyroptosis, metabolism, and tumor immune microenvironment. Clin Transl Med. 2021;11:e492.","journal-title":"Clin Transl Med"},{"key":"5357_CR54","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/2159-8290.CD-19-0672","volume":"10","author":"DA Erkes","year":"2020","unstructured":"Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2020;10:254\u201369.","journal-title":"Cancer Discov"},{"key":"5357_CR55","doi-asserted-by":"publisher","first-page":"e12168","DOI":"10.1002\/jev2.12168","volume":"10","author":"M Peng","year":"2021","unstructured":"Peng M, Ren J, Jing Y, Jiang X, Xiao Q, Huang J, et al. Tumour-derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia. J Extracell Vesicles. 2021;10:e12168.","journal-title":"J Extracell Vesicles"},{"key":"5357_CR56","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, Alotaibi AS, B\u00fccklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 2021;35:1843\u201363.","journal-title":"Leukemia"},{"key":"5357_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-020-0180-4","volume":"5","author":"C Fu","year":"2020","unstructured":"Fu C. Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity. Signal Transduct Target Ther. 2020;5:69.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05357-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05357-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T17:04:56Z","timestamp":1667235896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05357-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["5357"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05357-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experiments were approved by the Animal Ethics Committee of the Chongqing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"915"}}